Table 1 -.
High dimensional gene and protein expression technologies and application in human cancer studies.
| Technology | Reference | Cancer Type | Tissue | Cell types profiled | Therapy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor | Adj. normal | Lymph node | Blood | Immune | Tumor | Stromal | |||||
| Single-cell proteomics | CyTOF | Gadalla et al. 2019 | Ovarian, melanoma, breast | - | |||||||
| Subrahmanyam et al. 2018 | Melanoma | Anti-CTLA4, anti-PD-1 | |||||||||
| Krieg et al. 2018 | Melanoma | Anti-PD-1 | |||||||||
| Wu et al. 2020 | Pancreatic | GVAX, anti-CTLA4 | |||||||||
| Single-cell transcriptomics | scRNAseq | Nagaoka et al. 2020 | Gastric | Anti-PD-1, anti-IL-17 | |||||||
| Kieffer et al. 2020 | Breast | - | |||||||||
| Schelker at al. 2017 | Ovarian | - | |||||||||
| Peng et al. 2019 | Pancreatic | - | |||||||||
| Patel et al. 2014 | Glioblastoma | - | |||||||||
| Tirosh et al. 2016 | Melanoma | - | |||||||||
| Ma et al. 2019 | Hepatocellular, Cholangiocarcinoma | Anti-CTLA4, anti-PD-1 | |||||||||
| Bernard et al. 2019 | Pancreatic | - | |||||||||
| Schlesinger et al. 2020 | Pancreatic | - | |||||||||
| Sun et al. 2021 | Hepatocellular | - | |||||||||
| Davidson et al. 2020 | Melanoma | - | |||||||||
| Savas et al. 2018 | Breast | - | |||||||||
| Zheng et al. 2017 | Hepatocellular | - | |||||||||
| Guo et al. 2018 | NSCLC | - | |||||||||
| Sade-Feldman et al. 2018 | Melanoma | Anti-CTLA4, anti-PD-1 | |||||||||
| Spatial proteomics | MIBI | Angelo et al. 2014 | Breast | - | |||||||
| Keren et al. 2019 | Breast | - | |||||||||
| IMC | Giesen et al. 2014 | Breast | - | ||||||||
| Jackson et al. 2020 | Breast | - | |||||||||
| Xiang et al. 2020 | NSCLC | - | |||||||||
| Ho et al. 2020 | Hepatocellular carcinoma | Cabozantinib, anti-PD-1 | |||||||||
| CODEX | Schürch et al. 2020 | Colorectal | - | ||||||||
| MxIF | Yan et al. 2019 | Melanoma | - | ||||||||
| Spatial transcriptomics | Spatial transcriptomics | Moncada et al. 2020 | Pancreatic | - | |||||||
| Multi-omics | CITE-seq, scRNAseq | Cadot et al. 2020 | Leukemia (CLL) | Ibrutinib | |||||||
| CyTOF, scRNAseq | Gubin et al. 2018 * | Sarcoma | anti-CTLA4, anti-PD-1 | ||||||||
| scRNAseq, TCR, CyCIF | Yost et al. 2019 | Basal cell | Anti-PD-1 | ||||||||
| Azizi et al. 2018 | Breast cancer | - | |||||||||
| Jerby-Arnon et al. 2018 | Melanoma | Anti-PD-1 | |||||||||
| Wu et al. 2020 | NSCLC, endometrial, colorectal, renal | - | |||||||||
| scRNAseq, spatial transcriptomics, MIBI | Ji et al. 2020 | Squamous cell | - | ||||||||
| scRNAseq, IMC | Aoki et al. 2020 | Hodgkin lymphoma | - | ||||||||